E
Erasca D
D
ERAS
1.41000
USD
-0.04
(-2.76%)
مغلق
حجم التداول
38,350
الربح لكل سهم
-1
العائد الربحي
-
P/E
-2
حجم السوق
398,645,468
المقالات
العنوان: Erasca
القطاع: Healthcare
الصناعة: Biotechnology
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.